Background Interstitial lung disease (ILD) frequently complicates systemic autoimmune
disorders resulting in considerable morbidity and mortality. The connective tissue diseases …

Background Rituximab is often used as rescue therapy in interstitial lung disease (ILD)
associated with connective tissue disease (CTD), but has not been studied in clinical trials …

In very severe interstitial lung disease associated with connective tissue disease (CTD-ILD),
progressing despite maximal conventional immunosuppression, there is no effective …

Objective. CTD-associated interstitial lung disease (ILD) often fails to respond to
conventional immunomodulatory agents. There is now considerable interest in the use of …

Introduction/objectives To evaluate rituximab (RTX) effectiveness and safety in patients with
interstitial lung disease (ILD) related to connective tissue diseases (CTD). Methods …

OBJECTIVES Interstitial lung disease (ILD) is a key prognostic factor in connective tissue
disorders (CTDs). The aim of our study was to assess the changes in pulmonary functional …

Background: The American Thoracic Society convened an international, multidisciplinary
panel to develop clinical practice guidelines for the treatment of systemic sclerosis …

Objectives To assess the effect of rituximab (RTX) on the lung function parameters in SSc
interstitial lung disease (SSc-ILD) patients. Methods PubMed and Embase were searched to …

Objective To assess the real-world, long-term effectiveness of rituximab (RTX) as a rescue
therapy in patients with progressive rheumatoid arthritis-related interstitial lung disease (RA …

Interstitial lung disease (ILD) can be associated with all connective tissue diseases and is an
important cause of morbidity and mortality. The management of connective tissue disease …